{"id":8141,"date":"2023-07-24T16:36:13","date_gmt":"2023-07-24T14:36:13","guid":{"rendered":"http:\/\/www.seventure.fr\/wp-content\/uploads\/2023\/07\/Galecto-Completes-Dosing-in-52-Week-Phase-2b-GALACTIC-1-Trial-of-GB0139-in-Idiopathic-Pulmonary-Fibrosis.pdf"},"modified":"2023-07-24T16:36:13","modified_gmt":"2023-07-24T14:36:13","slug":"galecto-completes-dosing-in-52-week-phase-2b-galactic-1-trial-of-gb0139-in-idiopathic-pulmonary-fibrosis","status":"inherit","type":"attachment","link":"https:\/\/www.seventure.fr\/en\/galecto-completes-dosing-in-52-week-phase-2b-galactic-1-trial-of-gb0139-in-idiopathic-pulmonary-fibrosis\/galecto-completes-dosing-in-52-week-phase-2b-galactic-1-trial-of-gb0139-in-idiopathic-pulmonary-fibrosis\/","title":{"rendered":"Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis"},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false},"class_list":["post-8141","attachment","type-attachment","status-inherit","hentry"],"acf":[],"yoast_head":"\n